罗氏正试图赶超诺和诺德(NVO.US)和礼来(LLY.US)，后两家公司分别生产了价值数十亿美元的重磅药 物Wegovy和Zepbound。罗氏计划加快其实验性减肥药物的研发进程，这些药物在较小规模的试验中取 得的数据好坏参半，但目前正朝着临床开发的关键最后阶段迈进。 罗氏(RHHBY.US)将以高达35亿美元的价格收购生物制药公司89bio(ETNB.US)，这是该瑞士制药商进军 减肥药及相关疗法市场的最新举措。 罗氏在声明中表示，总部位于旧金山的89bio正在研发针对肝脏和心血管代谢疾病的创新疗法。处于后 期研发阶段的关键药物是pegozafermin，该药物有望成为治疗中度至重度代谢功能障碍相关脂肪性肝炎 (MASH)的最佳疗法。MASH是肥胖症中最常见的并发症之一。 当脂肪在肝脏中堆积时，就会形成MASH，引起炎症，并可能导致肝硬化和癌症等更严重的疾病。 罗氏将以每股14.50美元的现金收购89bio，股权总价值约为24亿美元。此外，股东还将获得一份不可交 易的或有价值权，最高可兑现每股6.00美元的现金，这使得交易总价值最高可达约35亿美元。数据显 示，89bio最新收盘价为8.08美元，市值接近1 ...

Roche Holding says it will acquire biopharmaceutical company 89bio in a deal valued at $3.5 billion, bolstering the Swiss pharmaceutical giant’s pipeline of cardiovascular, renal, and metabolic disease treatments https://t.co/9tmRggnAGn ...

Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments. ...

Core Viewpoint - 89bio, Inc. has entered into a merger agreement with Roche, with a cash acquisition price of $14.50 per share, representing a premium of approximately 79% over its closing stock price on September 17, 2025, and a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis [1][3][5] Company Overview - 89bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases, currently in Phase 3 trials for its lead candidate, pegozafermin [10] - Pegozafermin is a fibroblast growth factor 21 (FGF21) analog designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [10] Transaction Details - Roche will commence a tender offer to acquire all outstanding shares of 89bio for $14.50 per share, with an aggregate payment of $2.4 billion, plus a non-tradeable contingent value right (CVR) for up to an additional $6.00 per share [3][5] - The total transaction equity value could reach approximately $3.5 billion on a fully diluted basis, contingent upon the achievement of specified milestones [1][3][5] Contingent Value Rights (CVR) - The CVR will provide cash payments based on the achievement of certain milestones, including: - $2.00 per share upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients by March 31, 2030 - $1.50 per share if annual net sales reach at least $3.0 billion by December 31, 2033 - $2.50 per share if annual net sales reach at least $4.0 billion by December 31, 2035 [6] Strategic Implications - The merger aims to combine 89bio's innovative therapy with Roche's global development and commercialization capabilities, enhancing the potential benefits for patients and unlocking significant shareholder value [2] - Roche plans to integrate pegozafermin into its cardiovascular, renal, and metabolism portfolio, aiming to transform the standard of care for patients with moderate to severe MASH [2]

89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesityAcquisition supports Roche’s strategy as it enhances the company’s portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination developmentRoche to acquire 89bio for US$14.50 per share in cash at closing, representing a total equity value of approximately US$ ...

Accessibility StatementSkip Navigation Initially launched in 2012 in Vienna, Austria, by people with diabetes for people with diabetes, the mySugr app is today available in over 84 countries and 25 languages, enabling users to manage key therapy data. mySugr Glucose Insights, the Accu-Chek SmartGuide integration with the mySugr app, just received CE mark approval and is set to launch in the first countries later this year. Users can view and analyse their CGM glucose values and predictions in one place, alo ...

Core Viewpoint - The U.S. government, led by President Trump, is pressuring major pharmaceutical companies to lower drug prices in the U.S. by adhering to the "most-favored-nation" (MFN) pricing policy, which aims to align U.S. drug prices with the lowest prices in other developed countries [1][2][3] Group 1: Government Actions - President Trump has set a deadline of September 29 for pharmaceutical companies to comply with the MFN policy [2] - Multiple federal departments are being mobilized to support this initiative, indicating a coordinated effort to enforce the price reductions [2][3] Group 2: Pharmaceutical Companies Involved - Major pharmaceutical companies receiving Trump's letter include Eli Lilly (LLY.US), Pfizer (PFE.US), Merck (MRK.US), Gilead (GILD.US), Bristol-Myers Squibb (BMY.US), Johnson & Johnson (JNJ.US), Regeneron (REGN.US), Amgen (AMGN.US), AbbVie (ABBV.US), and several European firms such as Merck KGaA, Sanofi (SNY.US), GlaxoSmithKline (GSK.US), AstraZeneca (AZN.US), Novo Nordisk (NVO.US), Roche (RHHBY.US), and Novartis (NVS.US) [1] Group 3: Implications of High Drug Prices - The long-term high drug prices in the U.S. create significant pressure on both public welfare and government finances, making the MFN policy a direct and quantifiable approach to reduce costs [3] - The lack of price regulation in the U.S. compared to other countries contributes to higher drug prices, as U.S. pharmaceutical companies can raise prices without negotiation [3]

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

9月9日，余元堂司长会见罗氏诊断全球副总裁赛利格（Stefan Seliger）。王宇鹏副司长参加。 ...

Key Takeaways Roche presented new Vabysmo data from AVONELLE-X and SALWEEN at the Euretina Congress.Roche presented new Vabysmo data from AVONELLE-X and SALWEEN at the Euretina Congress.SALWEEN results showed vision gains and lesion resolution in polypoidal choroidal vasculopathy.Roche ((RHHBY) announced new data from two studies on ophthalmology drug Vabysmo (faricimab).Vabysmo is already approved in several countries for people with neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic ...